GPD1L and hepatocellular carcinoma: This unveiled a statistically significant inverse correlation between GPD1L mRNA levels in HCC cell lines and the AUC for lenvatinib (Spearman’s rho −0.55, p = 0.011), signifying a heightened drug sensitivity that corresponds to elevated GPD1L expression (Figure S12).